Corxel Pharmaceuticals, in collaboration with LENZ Therapeutics (LENZ), has released promising top-line results from the Phase 3 JX07001 clinical trial assessing LNZ100 for the treatment of presbyopia in China.
During this Phase 3 trial in China, evaluating both the safety and efficacy of LNZ100 (which contains 1.75% aceclidine HCl), the primary and key secondary endpoints were successfully met. The study demonstrated a statistically significant improvement of three lines or greater in Best Corrected Distance Visual Acuity (BCDVA) for near vision, while maintaining optimal distance vision, defined as retaining five or more letters.
The findings showed that 84% and 69% of the participants experienced improvements of two lines and three lines in visual acuity at 30 minutes, respectively. At three hours following treatment, 88% and 74% sustained these improvements, while preserving optimal distance vision. Moreover, at the 10-hour mark, 61% and 30% achieved two-line and three-line enhancements, respectively.
LNZ100 was found to be well-tolerated, with no serious treatment-related adverse events reported. Additionally, the company highlighted that 91% of participants reported a noticeable improvement in their near vision.
